Overview Submission Instructions Recent Publications Frequently Asked Questions Research Topics

Looking to publish in Lancet Haematology? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Try Livewrite Now

Lancet Haematology

The Lancet Haematology publishes original research, reviews, and opinion on international issues in clinical haematology, including haematology-oncology, red and white blood cell disorders, platelet disorders, stem cell transplantation and induced pluripotent stem cells, and transfusion medicine. It aims to influence clinical practice, explore global policy, and highlight practice-changing research in haematology.

Looking to publish in Lancet Haematology? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Try Livewrite Now

Subject Hematology

Impact Factor 17.7

Quartile Q1

Open Access Type Hybrid

ISSN 2352-3026

Invitation Only No

Cost Range USD 8,810 APC for open access in The Lancet Haematology as of Jan 1, 2026.

Submission Instructions

Lancet Haematology accepts the following article types. Click on an article type to view submission instructions.

Article

Cover Letter A covering letter is required for first submissions. The covering letter must explain why the paper should be published in Lancet Haematology rather than elsewhere and may state if fast-track publication is requested.

Abstract Articles must include a semistructured abstract. Article abstracts must not exceed 250 words, although randomised trial and some Article summaries are permitted up to 300 words. The abstract must be semistructured. The abstract must use the headings Background, Methods, Findings, Interpretation, and Funding.

Manuscript Articles should be up to 3500 words, with randomised controlled trial Articles allowed up to 4500 words, and the limit applies to manuscript text only. Primary research Articles must include a Research in context panel, and randomised trial reports must include a Randomisation and masking section within Methods. Articles must include Contributors, Declaration of interests, Role of the funding source, and data sharing statements, and primary research Articles must include a Research in context panel with the headings Evidence before this study, Added value of this study, and Implications of all the available evidence, while any AI writing assistance must be disclosed in the Acknowledgments.

References Articles must include no more than 30 references. References must use Vancouver style. References must be cited sequentially as superscript numbers after punctuation, list all six authors when there are six or fewer and the first three followed by et al when there are seven or more, and abbreviate journal names in standard Index Medicus form.

Figures & Tables Randomised trial Articles must include a trial profile and a table of baseline characteristics, observational study Articles must include a table of participant baseline characteristics, and systematic review or meta-analysis Articles must include a study-selection flow chart and a table of study characteristics, with a Forest plot usually included for meta-analyses. Text and tables must be submitted in a Word document, and figures must be submitted as editable files. Trial profiles, study-selection figures, and Forest plots must be supplied in editable format, and figures should be submitted as editable files such as .eps or .pdf.

Reformat to Lancet Haematology using Livewrite Premium

Review

Cover Letter A covering letter must be included with the submission. The covering letter must explain why the paper should be published in Lancet Haematology rather than elsewhere.

Abstract A 150-word unstructured summary must be included. The summary must not exceed 150 words. The summary must be unstructured. No mandatory headings for the summary are specified.

Manuscript Reviews should be up to 4500 words. Reviews should include a brief section entitled “Search strategy and selection criteria”. The manuscript must include a “Search strategy and selection criteria” section stating the sources searched and the inclusion and exclusion criteria, and any use of generative AI in developing the Review must be described in the Methods section with sufficient detail for replication.

References Reviews should have a maximum of 75 references. References must use Vancouver numbering style. References must be cited sequentially as superscript numbers after punctuation, with all authors listed for six or fewer authors and the first three followed by et al for seven or more authors.

Figures & Tables Use of up to 5–6 illustrations is encouraged. Tables must be supplied in a separate Word document from the main text, while the manuscript submission should include figures.

Reformat to Lancet Haematology using Livewrite Premium

Resource

Cover Letter A covering letter is required with first submissions. The covering letter must explain why the paper should be published in Lancet Haematology rather than elsewhere and should state if fast-track publication is requested.

Abstract Abstract requirements are not specified.

Manuscript The manuscript must include contributor information at the end of the text, declaration of interests and source of funding statements, and a generative AI disclosure statement in the acknowledgments if AI-assisted writing was used.

References References must use Vancouver numbering style. References must be cited sequentially in the text as superscript numbers after punctuation, list all authors if there are six or fewer and the first three followed by et al if there are seven or more, and cite personal communications and unpublished work in the text rather than in the reference list.

Figures & Tables First submissions should include the manuscript including tables and panels and should include figures, while tables must be supplied in a separate Word document from the main text. Table text must be editable with all grid lines visible, and figures must be provided in an editable file type unless they are photographs or MRI scans.

Reformat to Lancet Haematology using Livewrite Premium

Correspondence

Cover Letter A covering letter should be included with the first submission. The covering letter should explain why the paper should be published in Lancet Haematology rather than elsewhere and may state if fast-track publication is requested.

Abstract Abstract requirements are not specified.

Manuscript Correspondence should be no longer than 400 words. Correspondence should be written in response to previous content published in the journal. The manuscript must include individual author contributions at the end of the text, a Declaration of interests section, source of funding information, and an acknowledgment statement disclosing any use of generative AI in scientific writing with the model name, version, prompt, and how and where it was used.

References Correspondence should have no more than five references. References must use Vancouver numbering style. References must be cited sequentially as superscript numbers after punctuation, list all authors when there are six or fewer and the first three followed by et al when there are seven or more, and cite personal communications and unpublished work only in the text.

Figures & Tables Only one table or figure is permitted in Correspondence. Tables should be supplied in a separate Word document from the main text, and figures should be included with the submission. Table text must be editable and all grid lines visible.

Reformat to Lancet Haematology using Livewrite Premium

Comment

Abstract Abstract requirements are not specified.

Manuscript Unsolicited Comments must be no more than 750 words. The manuscript must include individual author contributions at the end of the text, a Declaration of interests section, a source of funding statement, and an acknowledgment disclosure of any generative AI use with the model name, version, exact prompt, and how and where it was used.

References Unsolicited Comments may include no more than ten references. References must use Vancouver numbering style. References must be cited sequentially as superscript numbers after punctuation, list all authors if there are six or fewer, and list the first three followed by et al if there are seven or more.

Figures & Tables Unsolicited Comments may include one figure, panel, or small table. The manuscript must include tables and panels, and figures must be included with the first submission.

Reformat to Lancet Haematology using Livewrite Premium

Perspectives

Cover Letter A covering letter is required for first submission. The covering letter must explain why the paper should be published in Lancet Haematology rather than elsewhere and may state whether fast-track publication is requested.

Abstract Abstract requirements are not specified.

Manuscript The manuscript must include contributors and declaration of interests statements at the end of the text, source of funding information, and an acknowledgment statement disclosing any use of generative AI in scientific writing with the model name, version, exact prompt, and how and where it was used.

References References must use Vancouver numbering style. References must be cited sequentially as superscript numbers after punctuation, list all authors when there are six or fewer or the first three followed by et al when there are seven or more, and include URL plus access date for online material.

Figures & Tables The manuscript for first submission should include tables and panels, figures should also be included, and tables must be supplied in a separate Word document from the main text. Table text must be editable, and figures must be provided in an editable file type unless they are photographs or MRI scans.

Reformat to Lancet Haematology using Livewrite Premium

Recent Publications

Guidelines for the management of acute porphyria: recommendations from the International Porphyria Network

Yonatan Edel, Penelope E Stein, Hassan Kawtharany, Aasne K Aarsand, Michael Badminton, Manisha C Balwani, Herbert L Bonkovsky, Maria Domenica Cappellini, David Cassiman, Jean-Charles Deybach, Liz Gill, Pauline Harper, Richard Hift, Raili Kauppinen, Aneta Ivanova, Janneke Langendonk, Matteo Marcacci, Anna-Elizabeth Minder, Hetanshi Naik, Elena Pischik, Petro E Petrides, David Rees, Bruce Richie, Eliane Sardh, Caroline Schmitt, Danja Schulenburg-Brand, Mark Sonderup, Ulrich Stölzel, Jordi To-Figueras, Paolo Ventura, Nils Wohmann, Reem Mustafa, Sverre Sandberg

10.1016/s2352-3026(26)00044-x

View Publication

Mental health at the heart of haematology

The Lancet Haematology

10.1016/s2352-3026(26)00103-1

View Publication

Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial

Franck E Nicolini, Gabriel Etienne, Françoise Huguet, Aude Charbonnier, Gabrielle Roth-Guépin, Martine Escoffre-Barbe, Viviane Dubruille, Hyacinthe Johnson-Ansah, Philippe Rousselot, Laurence Legros, Anne Parry, Lydia Roy, Valérie Coiteux, Pascal Lenain, Jean-Christophe Ianotto, Charlotte Doublet, Corentin Orvain, Marion Simonet-Boissard, Marie-Lorraine Chrétien, Amélie Penot, Mathieu Meunier, Shanti Amé, Eric Hermet, Philippe Quittet, Simona Lapusan, Vérane Schwiertz, Jean-Michel Cayuela, Carole Mauté, Delphine Réa, Stéphane Morisset, François-Xavier Mahon, Stéphanie Dulucq

10.1016/s2352-3026(26)00043-8

View Publication

Leveraging TikToks in clinical practice

Warren B Fingrut

10.1016/s2352-3026(26)00101-8

View Publication

Very early [18F]FDG-PET-guided targeted therapy in untreated advanced-stage classic Hodgkin lymphoma (EORTC-1537-COBRA): primary results of a single-arm, multicentre, phase 2 trial

Martin Hutchings, Arjan Diepstra, Anna Sureda Balari, Susana Carvalho, Andrej Vranovsky, Walter Noordzij, Annika Loft, Anne Arens, Sophie Teesink, Lydia Visser, Wendy Stevens, Berthe M P Aleman, F J Sherida H Woei-A-Jin, Maria Viguria, Kirsten Saevels, Liane Te Boome, Sanne Tonino, Paul Meijnders, Eva Domingo Domènech, Caroline Hasselbalch Riley, Laure Musekera, Sarah Nuyens, Cedric Mallien, Ward Sents, Emanuel Bührer, Catherine Fortpied, Wouter J Plattel

10.1016/s2352-3026(26)00068-2

View Publication

Frequently asked questions

How long does it take to publish?

6 days submission to first decision; 44 days submission to decision after review; 87 days submission to acceptance; 60 days acceptance to online publication

Reformat to Lancet Haematology using Livewrite Premium

What are the publication costs?

The Lancet Haematology is a hybrid journal with an open access APC of USD 8,810 as of Jan 1, 2026. APCs are paid upon acceptance and do not include taxes. Discounts and waivers are available in some cases.

Reformat to Lancet Haematology using Livewrite Premium

Research Topics

Lymphoma Diagnosis and Treatment Myeloproliferative Neoplasms: Diagnosis and Treatment Acute Myeloid Leukemia Research Hemoglobinopathies and Related Disorders Chronic Lymphocytic Leukemia Research Multiple Myeloma Research and Treatments Acute Lymphoblastic Leukemia research CAR-T cell therapy research Hematopoietic Stem Cell Transplantation Venous Thromboembolism Diagnosis and Management Iron Metabolism and Disorders Chronic Myeloid Leukemia Treatments Platelet Disorders and Treatments Blood groups and transfusion Protein Degradation and Inhibitors Blood transfusion and management Viral-associated cancers and disorders Blood donation and transfusion practices Hemophilia Treatment and Research CNS Lymphoma Diagnosis and Treatment Blood Coagulation and Thrombosis Mechanisms Childhood Cancer Survivors' Quality of Life Erythropoietin and Anemia Treatment Atrial Fibrillation Management and Outcomes Cutaneous lymphoproliferative disorders research

Related Journals

American Journal Of Preventive Medicine Elsevier BV

International Journal Of Oral And Maxillofacial Surgery Elsevier BV

Diabetes Research And Clinical Practice Elsevier BV

American Journal Of Surgery Elsevier BV

Trends In Anaesthesia And Critical Care Elsevier BV

Emergency Medicine Clinics Of North America Elsevier BV